Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 10/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444516 | 0.90 | MAP2K7 (0.48) | MAP2K7KDRBRAFMAPK14TNNI3K | |
| SCHEMBL14447612 | 0.89 | MAP2K7 (0.48) | MAP2K7AURKARPS6KB1KDRBRAF | |
| SCHEMBL5319331 | 0.89 | MAP2K7 (0.47) | MAP2K7KDRBRAFMAPK14TNNI3K | |
| SCHEMBL5446984 | 0.88 | MAP4K4 (0.48) | MAP2K7AURKARPS6KB1KDRBRAF | |
| SCHEMBL14447614 | 0.87 | MAP2K7 (0.46) | MAP2K7KDRBRAFMAPK14TNNI3K | |
| SCHEMBL14447587 | 0.86 | MAP2K7 (0.54) | MAP2K7KDRBRAFMAPK14TNNI3K | |
| SCHEMBL5445983 | 0.86 | MAP2K7 (0.48) | MAP2K7AURKARPS6KB1KDRBRAF | |
| SCHEMBL14447620 | 0.86 | MAP2K7 (0.45) | MAP2K7KDRBRAFMAPK14TNNI3K | |
| SCHEMBL5448231 | 0.84 | AURKA (0.41) | MAP2K7AURKARPS6KB1KDRBRAF | |
| SCHEMBL5336916 | 0.84 | MAP2K7 (0.50) | MAP2K7KDRTNNI3KABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | MAP2K7 141/4885AURKA 921/4885RPS6KB1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.